Articles On Amplia Therapeutics (ASX:ATX)

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

So basically, this is how I read it. Because of two really screwball takeover ideas involving the A2 Milk Co and AGL Energy —  two of the more screwball companies floating about on the benchmark index — the S&P/ASX200 is higher on Monda...

Amplia Therapeutics’ (ATX) pancreatic cancer drug, AMP945 has been shown to improve the effectiveness of Gemcitabine and Abraxane in a model of human pancreatic cancer The study conducted at the Garvan Institute established pancreatic tumo...

At the time of writing, the ASX 200 Health Index (XHJ) is up by another 3.3%, while the benchmark ASX 200 has risen by 0.5%. Cancer and fibrosis focused biotech Amplia Therapeutics (ASX:ATX) said its AMP945 drug improves effectiveness of cu...

Amplia (ASX:ATX) has reported the publication of a key paper in the peer-reviewed journal Science Advances that shows pre-treatment with a FAK inhibitor improves the effectiveness of chemotherapy in a preclinical model of pancreatic...

Wall Street mixed on subdued Fed minutes Investors breathed a sigh of relief overnight after the Fed minutes were less hawkish than many expected. The minutes showed that rates will be raised in March along with a reduction in the size of t...

Researchers at the Garvan Institute have shown that the addition of AMP945 pre-treatment to a gemcitabine/Abraxane® chemotherapy regimen increased survival by 33%.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

“The AACR is one of the most recognised international forums for cancer research and we are delighted that the results of our phase one trial have been selected for presentation at this prestigious meeting,” says CEO.

“While 2021 was a challenging year for everyone, I am extremely proud of what our team at Amplia has been able to achieve. In the last quarter of 2021, we put in place all the elements to make 2022 a watershed year for the company," says CE...

Amplia Therapeutics (ASX: ATX) is a step closer to phase 2 clinical trials in pancreatic cancer and lung fibrosis after completing a manufacturing run of its lead focal adhesion kinase (FAK) inhibitor drug AMP945. The company’s contractor h...

Amplia Therapeutics (ATX) completes manufacture of its clinical-stage drug candidate ahead of planned trials A two-kilogram batch of the company’s AMP945 will be used in toxicology studies and phase two clinical trials in pancreatic cancer...

The batch was produced on time and within budget and represents a big step up from the 1-kilogram batch that’s been manufactured under GMP conditions previously.

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

“Our priorities for 2022 are clear – our goal will be to build on the solid foundations of the last 12 months and maintain this momentum as we move towards two phase-two trials in the new year,” says CEO.

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The cash injection will fund the first stage of phase two clinical trials for AMP945, as well as manufacturing and further pre-clinical studies and additional working capital.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has been granted a $2.1 million funding facility to accelerate work on its second focal adhesion kinase (FAK) inhibitor drug AMP886 for treating cancers and fibrotic disease. The company...

Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan The $2.1 million will be awarded in two tranches: $1.3m in December this year and $0.8 million in the quarter ending March 31, 2022...

Amplia has designed a Phase 2 clinical trial of AMP945 in pancreatic cancer patients and plans to initiate patient recruitment at Australian sites in the first quarter of calendar 2022.

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The company is optimistic about the results of its Phase 1 clinical trial with results supporting further development of AMP945 as a treatment for cancer and fibrosis.

Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has received new data from a recent Phase 1 clinical trial which demonstrates the ability of lead drug AMP945 to inhibit focal adhesion kinase (FAK) in healthy human volunteer...

Amplia targets human trials for pancreatic cancer drug Noxopharm subsidiary enters licence agreement with Hudson Insitiute of Medical Research $7.2 million placement and $2 million SPP launched by Pharmaxis to support next phase of clinica...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The data will be used to further refine the doses of AMP945 to be used in a Phase 2 clinical trial in patients with pancreatic cancer and will provide guidance for the Phase 2 trial in pulmonary fibrosis planned for the second half of 2022.

The capital raise consists of a placement to institutional and sophisticated investors to raise $5.4 million and a one-for-four fully underwritten pro-rata non-renounceable entitlement offer to raise $7 million.

Proceeds from the placement and entitlement offer will be used to fund the first stage of a Phase 2 clinical trial for AMP945, manufacturing and further pre-clinical studies.

The ASX had a positive finish to the week taking its weekly return to 1.8%. Today the ASX 200 closed at 7,457 points, 0.39% higher than yeterday. Tech was heavily sold off, shedding 1.64% but almost all other sectors were in the green with...

The ASX rose 0.48% today to reach its highest point in the week. While energy lost 2% most other sectors were in the green with tech and financials gaining over 1%. Today’s gains came despite the Federal Reserve unveiling a tapering of stim...

Pharmaceutical company Amplia Therapeutics (ATX) enters into a trading halt as it plans an upcoming capital raise It is not known how much the company is aiming to raise or where the funds will be spent Under the halt, company shares will...

The company has also entered a trading halt as it undertakes a capital-raising process. The halt is in place until Monday, November 8, or when an announcement is released to the market.

Amplia Therapeutics is raising $12.4 million to fund human clinical trials and drug manufacturing for its drug candidate designed to slow cancer progression.

Amplia Therapeutics (ASX: ATX) has appointed experienced spearhead of pancreatic cancer treatments Dr José Iglesias as clinical advisor to assist with development of its cancer and fibroid drugs. The company pointed out that Dr Iglesias was...

José Iglesias MD will join the ATX team as a clinical advisor, providing more than 30 years of experience in the pharmaceutical industry.

Many successful investors in healthcare have made money by patiently backing companies that are quietly and strategically trying to solve big problems, like Australian biotech company Amplia Therapeutics (Amplia, ASX:ATX).

Clinical development company Amplia Therapeutics (ASX: ATX) has received a research and development tax incentive refund from the federal government for expenditure related to advancing its focal adhesion kinase (FAK) inhibitors for cancer...

The trial was completed during the first half of 2021 and leads into the company’s planned Phase 2 clinical trial in pancreatic cancer patients.

George will replace Jeff Carter, who is stepping down from the role after being the company’s CFO for more than eight years. 

New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned Phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prio...

FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus on pancreatic and ovarian cancer.

Amplia Therapeutics (ASX:ATX), which is developing new drugs for the treatment of cancer and fibrosis, has announced the publication of a paper from the Garvan Institute of Medical Research.